Skip to main content

20 Result(s)

within M. L. Slevin Remove this filter

and

  1. Article

    Open Access

    Irinotecan, cisplatin and mitomycin in inoperable gastro-oesophageal and pancreatic cancers – a new active regimen

    Irinotecan, mitomycin and cisplatin all demonstrate activity in gastro-oesophageal cancers. This novel combination was administered to outpatients with previously untreated inoperable gastro-oesophageal or pan...

    S Slater, J Shamash, P Wilson, C J Gallagher, M L Slevin in British Journal of Cancer (2002)

    Download PDF (88 KB) View Article

  2. Article

    Open Access

    An analysis of first-time enquirers to the CancerBACUP information service: variations with cancer site, demographic status and geographical location

    A retrospective comparison of cancer incidence data and, where relevant, population data with 16 955 first-time users (patients, relatives and friends) of a national cancer information service (CancerBACUP) du...

    M Boudioni, K McPherson, J Mossman, M Boulton, A L Jones… in British Journal of Cancer (1999)

    Download PDF (257 KB)

  3. No Access

    Article

    Book reviews

    R. K. S. Phillips, M. L. Slevin in International Journal of Colorectal Disease (1990)

  4. No Access

    Article

    A phase II study of ifosfamide and cisplatin chemotherapy for metastatic or relapsed carcinoma of the cervix

    A total of 44 women received a combination of ifosfamide (1.5 g/m2 daily x5) and cisplatin (50 mg/m2 on day 1 only) as first-line chemotherapy for recurrent or metastatic carcinoma of the cervix. In all, 12/42 (3...

    R. E. Coleman, J. M. Clarke, M. L. Slevin… in Cancer Chemotherapy and Pharmacology (1990)

  5. No Access

    Chapter and Conference Paper

    Kinetic Analysis with Probability Map** in Radioimmunoscintigraphy

    Radioimmunoscintigraphy, RIS, is currently undertaken with, by nuclear medicine standards, a poor radiopharmaceutical since usually less than one per cent of the administered activity is taken up by the tumor....

    M. Granowska, K. E. Britton, M. Crowther… in Radiolabeled Monoclonal Antibodies for Ima… (1988)

  6. No Access

    Article

    Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (Trial 1) and in combination with 5-fluorouracil (Trial 2) in advanced colorectal cancer

    Sixty-five patients with advanced colorectal cancer were randomised to one of two schedules of recombinant alpha-2 interferon (IFN). In the first study, 36 patients received single-agent IFN, either 50×106 U/m2 i...

    P. I. Clark, M. L. Slevin, R. H. Reznek… in International Journal of Colorectal Disease (1987)

  7. No Access

    Article

    A phase II study of ifosfamide in advanced and relapsed carcinoma of the cervix

    Forty-one patients with advanced progressing carcinoma of the cervix were treated with ifosfamide 1.5 g/m2 daily in a 30-min infusion for 5 days every 3 weeks. The overall response rate (complete + partial) was 1...

    R. E. Coleman, P. G. Harper, C. Gallagher… in Cancer Chemotherapy and Pharmacology (1986)

  8. No Access

    Article

    The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide

    There is no information on the effect of food or concurrent drug administration on the bioavailability of oral etoposide, despite the fact that treatment is frequently administered over several days and most o...

    V J Harvey, M L Slevin, S P Joel, A Johnston, P F Wrigley in British Journal of Cancer (1985)

  9. No Access

    Article

    The pharmacokinetics of subcutaneous bolus cytosine arabinoside in an arachis oil plus aluminium distearate suspension

    An attempt was made to create a delayed release preparation of cytosine arabinoside (araC) which could be administered subcutaneously, and would produce plasma levels similar to steady state infusion concentra...

    M. L. Slevin, E. M. Piall, A. Johnston, D. A. Levison… in Investigational New Drugs (1984)

  10. No Access

    Article

    The bioavailability of oral intermediate-dose methotrexate

    The oral bioavailability of methotrexate is variable and may be dose-dependent. The absorption of ‘interval’ oral methotrexate, which is given between cycles of chemotherapy, is unknown.

    V. J. Harvey, M. L. Slevin, R. C. Woollard… in Cancer Chemotherapy and Pharmacology (1984)

  11. No Access

    Article

    Delayed-release bleomycin

    Experimental and clinical evidence indicates that bleomycin by continuous infusion is superior to intermittent administration. Continuous infusion is less convenient, however. It has been suggested that a susp...

    M. L. Slevin, V. J. Harvey, G. W. Aherne… in Cancer Chemotherapy and Pharmacology (1984)

  12. No Access

    Article

    The efficiency of protective gloves used in the handling of cytotoxic drugs

    A range of clinical and industrial gloves have been evaluated to determine their ability to exclude penetration by cytotoxic drugs.

    M. L. Slevin, L. M. Ang, A. Johnston, P. Turner in Cancer Chemotherapy and Pharmacology (1984)

  13. No Access

    Article

    High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma

    Twenty-six patients with acute leukaemia and 14 with high-grade lymphoma received cytosine arabinoside (ara-C) at a twice daily dose of 2 g/m2 administered as a 3-h infusion. Thirty-four patients received 12 dose...

    Ama Rohatiner, M. L. Slevin, H. S. Dhaliwal… in Cancer Chemotherapy and Pharmacology (1984)

  14. No Access

    Chapter

    Short Term Chemotherapy for Acute Myelogenous Leukaemia

    The use of increasingly intensive chemotherapy for the treatment of acute nyelogenous leukaemia has led to an apparent improvement in the prognosis of younger patients. It has become possible to support them e...

    T. A. Lister, W. Gregory, A. Z. S. Rohatiner… in Minimal Residual Disease in Acute Leukemia (1984)

  15. No Access

    Article

    Adjuvant oral Razoxane (ICRF 159) in resectable colo-rectal cancer

    M. L. Slevin, V. J. Harvey, P. F. M. Wrigley… in Cancer Chemotherapy and Pharmacology (1983)

  16. No Access

    Article

    Subcutaneous infusion of cytosine arabinoside

    The administration of cytosine arabinoside (araC) by continuous IV infusion requires the patient to be in hospital and have prolonged IV cannulation. In this study the pharmacokinetics of araC during continuou...

    M. L. Slevin, E. M. Piall, G. W. Aherne… in Cancer Chemotherapy and Pharmacology (1983)

  17. No Access

    Article

    Letter to the editor

    M. L. Slevin, V. J. Harvey, P. F. M. Wrigley… in Cancer Chemotherapy and Pharmacology (1983)

  18. No Access

    Chapter and Conference Paper

    Short-term Therapy for Acute Myelogenous Leukaemia in Younger Patients

    It has now been repeatedly demonstrated that it is possible to achieve complete remission (CR) in the majority of younger adults with acute myelogenous leukaemia (AML) [4, 5, 7, 11, 12], and that approximately...

    T. A. Lister, A. Z. S. Rohatiner, M. L. Slevin… in Modern Trends in Human Leukemia V (1983)

  19. No Access

    Chapter and Conference Paper

    The Clinical Pharmacology of Cytosine Arabinoside

    There is now little doubt that a proportion of patients with adult acute myelogenous leukaemia will achieve long-term survival and possibly cure with combination chemotherapy. Cytosine arabinoside (araC) is on...

    M. L. Slevin, E. M. Piall, G. W. Aherne, A. Johnston… in Modern Trends in Human Leukemia V (1983)

  20. No Access

    Article

    A phase I and II study of m-AMSA in acute leukaemia

    Thirty-two patients with relapsed or resistant acute leukaemia were treated with m-AMSA at doses ranging from 50–150 mg/m2 daily for 5 days.

    M. L. Slevin, M. S. Shannon, H. G. Prentice… in Cancer Chemotherapy and Pharmacology (1981)